Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (18)
Bipin Sethi, Subhankar Chowdhury, Supratik Bhattacharya, Sagar Katare, Sachin Suryawanshi & Hanmant Barkate. (2022) Real-world assessment of effectiveness and safety profile of remogliflozin etabonate in management of type 2 diabetes mellitus. International Journal of Diabetes in Developing Countries 43:2, pages 214-225.
Crossref
Crossref
Youn Huh & Young Sik Kim. (2022) Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care. BMC Primary Care 23:1.
Crossref
Crossref
Angeliki M Angelidi, Matthew J Belanger, Alexander Kokkinos, Chrysi C Koliaki & Christos S Mantzoros. (2022) Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocrine Reviews 43:3, pages 507-557.
Crossref
Crossref
Derun Taner Ertugrul, Erdal Kan, Cigdem Bahadir Tura, Haci Bayram Tugtekin, Hayati Ayakta, Mehmet Celebioglu, Ceren Yılmaz, Onur Utebay, Ilhan Yetkin, Eren Gurkan, Kerem Sezer, Ramazan Gen, Suleyman Ozcaylak, Yildiz Okuturlar, Mehmet Coskun, Nilgun Govec Giynas, Harun Aysal, Ayca Serap Erdem, Mustafa Aydemir, Okan Bakiner, Emre Cicekli, Deniz Gezer, Ramazan Kaya, Levent Kebapcilar, Umit Cinkir, Memmune Sena Ulu, Canan Ersoy, Mustafa Timur Kagan, Berna Dalmis Ekiz, Faruk Kilinc, Kevser Onbasi, Mahir Cengiz, Mehmet Celik, Metin Guclu, Metin Sarıkaya, Ozcan Ozbag, Ramazan Sari, Rifki Ucler, Selcuk Sezikli, Mustafa Araz, Erdal Gundogan, Erhan Bozkurt, Murat Akbas, Rifat Bozkus, Baris Akinci, Ersen Karakilic, Murat Medeni, Ozgur Keskek, Enver Sukru Goncuoglu, Sayid Shafi Zuhur, Ahmet Ziya Sahin, Kursat Dal, Mehmet Ali Eren, Tugba Arkan, Bengur Taskiran, Gokturk Kilinc, Emre Bozkirli, Sabriye Ozkaya Kafesciler, Nuh Kafesciler, Esra Cil Sen, Sahin Doganay, Caglar Koseoglu, Tamer Tetiker, Taner Bayraktaroglu, Aytekin Oguz, Esra Ataoglu, Muhammed Mustafa Demirpence, Semra Tursun, Inan Anaforoglu, Omur Tabak, Rifat Emral, Kubilay Karsidag, Oguzhan Sitki Dizdar, Alparslan Kemal Tuzcu, Mustafa Caliskan, Pinar Sirmatel, Yasin Kocaoz, Hakan Dogan, Semin Melahat Fenkci, Ibrahim Sahin & Zuleyha Karaca. (2021) Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes. International Journal of Diabetes in Developing Countries 42:1, pages 147-160.
Crossref
Crossref
Nassim Mahtal, Olivia Lenoir & Pierre-Louis Tharaux. (2021) Glomerular Endothelial Cell Crosstalk With Podocytes in Diabetic Kidney Disease. Frontiers in Medicine 8.
Crossref
Crossref
Aml Mohamed Nada & Mariam Adel Younan. (2021) Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882199536.
Crossref
Crossref
Jung-Fu Chen, Yun-Shing Peng, Chung-Sen Chen, Chin-Hsiao Tseng, Pei-Chi Chen, Ting-I Lee, Yung-Chuan Lu, Yi-Sun Yang, Ching-Ling Lin, Yi-Jen Hung, Szu-Ta Chen, Chieh-Hsiang Lu, Chwen-Yi Yang, Ching-Chu Chen, Chun-Chuan Lee, Pi-Jung Hsiao, Ju-Ying Jiang & Shih-Te Tu. (2020) Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan. PeerJ 8, pages e9998.
Crossref
Crossref
Yangli Ye, Chenhe Zhao, Jing Liang, Yinqiu Yang, Mingxiang Yu & Xinhua Qu. (2019) Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk. Frontiers in Pharmacology 9.
Crossref
Crossref
A Ram Hong, Bo Kyung KooSang Wan KimKa Hee YiMin Kyong Moon. (2019) Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice. Diabetes & Metabolism Journal 43:5, pages 590.
Crossref
Crossref
Sang Hyun ParkYoung Ju ChoiEun-Jung Rhee & Kab Bum Huh. (2019) Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea. Endocrinology and Metabolism 34:1, pages 70.
Crossref
Crossref
Murat Calapkulu, Soner Cander, Ozen Oz Gul & Canan Ersoy. (2019) Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:1, pages 284-288.
Crossref
Crossref
Raminderjit Kaur, Manpreet Kaur & Jatinder Singh. (2018) Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovascular Diabetology 17:1.
Crossref
Crossref
M. V. Karg, A. Bosch, D. Kannenkeril, K. Striepe, C. Ott, M. P. Schneider, F. Boemke-Zelch, P. Linz, A. M. Nagel, J. Titze, M. Uder & R. E. Schmieder. (2018) SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovascular Diabetology 17:1.
Crossref
Crossref
Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami, Kunio Hieshima, Akira Yoshida, Katsunori Jinnouchi, Hiroyuki Nishimura, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara & Tomio Jinnouchi. (2018) Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis 25:6, pages 467-476.
Crossref
Crossref
Abdullah Kaplan, Emna Abidi, Ahmed El-Yazbi, Ali Eid, George W. Booz & Fouad A. Zouein. (2018) Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Failure Reviews 23:3, pages 419-437.
Crossref
Crossref
Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring & Steven G. Terra. (2018) Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes, Obesity and Metabolism 20:3, pages 520-529.
Crossref
Crossref
Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V. Karg, Peter Bramlage & Roland E. Schmieder. (2017) A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovascular Diabetology 16:1.
Crossref
Crossref
G.P. Fadini, G. Zatti, A. Consoli, E. Bonora, G. Sesti, A. Avogaro, A. Consoli, G. Formoso, D. Antenucci, G. Grossi, A. Pucci, G. Sesti, F. Andreozzi, L. Indrieri, G. Capobianco, A. Gatti, R. Bonadonna, I. Zavaroni, A. Dei Cas, G. Felace, P. Li Volsi, R. Buzzetti, G. Leto, F. D'Angelo, S. Morano, A. Giaccari, G. Sorice, E. Orsi, A. Carlo Bossi, F. Querci, E. Duratorre, C. Malagola, I. Franzetti, P. Silvia Morpurgo, M. Boemi, M. Petrelli, G. Aimaretti, I. Karamouzis, F. Cavalot, G. Saglietti, G. Gruden, E. Devangelio, G. Cazzetta, O. Lamacchia, S. Cervone, L. Frittitta, S. Arena, A. Di Benedetto, S. Piro, C. Giordano, M. Rizzo, R. Chianetta, C. Mannina, A. Solini, A. Natali, R. Anichini, F. Dotta, B. Fattor, A. Avogaro, G.P. Fadini, E. Bonora, M. Cigolini, N. Simioni, V. Frison, M. Poli, A. Lapolla, N. Cristiano Chilelli & C. Vinci. (2017) Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes). Nutrition, Metabolism and Cardiovascular Diseases 27:12, pages 1089-1097.
Crossref
Crossref